CSBIO(SZ:300255)2022-12-06 23:52Group 1: Company Overview and Sales Performance - The company is actively expanding its low molecular weight heparin calcium injection sales, showing stable growth compared to the same period last year [2] - The sales of Daptomycin injection are expected to see significant growth as the company actively develops the market [2] - The heparin raw material sales are anticipated to experience good growth this year due to negotiations with several large clients [2] Group 2: Product Development and Market Strategy - The company is preparing registration materials for sodium hyaluronate, with strong market demand, particularly in the beauty industry [3] - Plans are in place to develop injectable-grade sodium hyaluronate in the future [3] - The company is preparing registration materials for heparin and low molecular weight heparin formulations for international market entry [3] Group 3: Clinical Trials and New Initiatives - The first phase of clinical trials for Abexinostat is expected to be completed in Q3 of this year, with preparations for the second phase already underway [3] - The company is set to open its first blood dialysis center and is committed to ensuring operational quality [3] - Future collaborations include establishing a specialized oncology hospital in China with a U.S. partner and developing new anti-tumor drugs [3]